Covid cure reports 90% effectiveness

WASHINGTON, D.C.: Pfizer Inc. said on Friday (Saturday in Manila) that its experimental antiviral pill for Covid-19 cut rates of hospitalization and death by nearly 90 percent in high-risk adults, as the drugmaker joined the race for an easy-to-use medication to treat the coronavirus.

Currently most Covid-19 treatments require an IV or injection. Competitor Merck's Covid-19 pill is already under review at the Food and Drug Administration after showing strong initial results, and on Thursday the United Kingdom became the first country to OK it.